Ultralife (ULBI) Common Equity (2010 - 2026)

Ultralife's Common Equity history runs 17 years deep, the most recent figure standing at $129.6 million for Q1 2026.

• On a quarterly basis, Common Equity fell 5.11% year-over-year to $129.6 million in Q1 2026; TTM through Mar 2026 was $129.6 million, a 5.11% decrease from a year earlier, with the FY2025 full-year figure at $130.1 million, down 3.02% from the prior year.
• Common Equity held at $129.6 million in Q1 2026 per ULBI's latest filing, from $130.1 million in the prior quarter.
• Across five years, Common Equity topped out at $138.6 million in Q2 2025 and bottomed at $115.3 million in Q3 2022.
• The 5-year median for Common Equity is $128.9 million (2024), against an average of $126.7 million.
• Across the five-year window, Common Equity advanced 11.42% in 2024 and decreased 5.11% in 2026, its largest moves.
• Year by year, Common Equity stood at $116.4 million in 2022, then rose by 7.75% to $125.4 million in 2023, then climbed by 6.98% to $134.2 million in 2024, then slipped by 3.02% to $130.1 million in 2025, then declined by 0.39% to $129.6 million in 2026.
• Per Business Quant, the three latest ULBI Common Equity figures stand at $129.6 million (Q1 2026), $130.1 million (Q4 2025), and $137.4 million (Q3 2025).